BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31041628)

  • 1. Selection and Characteristics of Patients with Peritoneal Dissemination from Appendiceal Cancer with Exceptional/Poor Survival After CRS/HIPEC.
    Munoz-Zuluaga C; King MC; Sardi A; Ledakis P; Sittig M; Nieroda C; MacDonald R; Gushchin V
    Ann Surg Oncol; 2019 Jul; 26(7):2268-2275. PubMed ID: 31041628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Munoz-Zuluaga C; Sardi A; King MC; Nieroda C; Sittig M; MacDonald R; Gushchin V
    Ann Surg Oncol; 2019 Feb; 26(2):473-481. PubMed ID: 30523470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
    Munoz-Zuluaga CA; King MC; Ledakis P; Gushchin V; Sittig M; Nieroda C; Zambrano-Vera K; Sardi A
    Eur J Surg Oncol; 2019 Sep; 45(9):1598-1606. PubMed ID: 31109821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.
    Reghunathan M; Kelly KJ; Valasek MA; Lowy AM; Baumgartner JM
    Ann Surg Oncol; 2018 Mar; 25(3):702-708. PubMed ID: 29282599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining "Complete Cytoreduction" After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis.
    Munoz-Zuluaga CA; King MC; Diaz-Sarmiento VS; Studeman K; Sittig M; MacDonald R; Nieroda C; Zambrano-Vera K; Gushchin V; Sardi A
    Ann Surg Oncol; 2020 Dec; 27(13):5026-5036. PubMed ID: 32705513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix.
    Lopez-Ramirez F; Gushchin V; Sittig M; King MC; Baron E; Nikiforchin A; Nieroda C; Sardi A
    Ann Surg Oncol; 2022 Jun; 29(6):3390-3401. PubMed ID: 35133518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries.
    Votanopoulos KI; Bartlett D; Moran B; Haroon CM; Russell G; Pingpank JF; Ramalingam L; Kandiah C; Chouliaras K; Shen P; Levine EA
    Ann Surg Oncol; 2018 Mar; 25(3):674-678. PubMed ID: 29288288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC.
    Ward EP; Okamuro L; Khan S; Hosseini M; Valasek MA; Ronquillo N; Kelly KJ; Veerapong J; Lowy AM; Baumgartner J
    Hum Pathol; 2021 Jul; 113():104-110. PubMed ID: 33905776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
    Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA
    Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
    El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A
    Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection.
    Enomoto LM; Choudry MH; Bartlett DL; Totin L; Mann GN; Skitzki JJ; Perry KC; Votanopoulos KI; Levine EA; Shen P
    Ann Surg Oncol; 2020 Jan; 27(1):107-114. PubMed ID: 31368017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy.
    Sutton PA; O'Dwyer ST; Barriuso J; Aziz O; Selvasekar CR; Renehan AG; Wilson MS
    Surg Oncol; 2021 Sep; 38():101572. PubMed ID: 33915487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term survival analysis after hyperthermic intraperitoneal chemotherapy with oxaliplatin as a treatment for appendiceal peritoneal carcinomatosis.
    Masckauchan D; Trabulsi N; Dubé P; Aubé-Lecompte ME; Cloutier AS; Mitchell A; Sideris L
    Surg Oncol; 2019 Mar; 28():69-75. PubMed ID: 30851915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Patients with High-Grade, High-Volume Disseminated Mucinous Appendiceal Neoplasms.
    Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2016 Feb; 23(2):382-90. PubMed ID: 26429720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Yong ZZ; Tan GHC; Shannon N; Chia C; Teo MCC
    World J Surg Oncol; 2019 Aug; 17(1):138. PubMed ID: 31391066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.